MRI guided focal HDR brachytherapy for localized prostate cancer: Toxicity, biochemical outcome and quality of life

Jemal, 2015, Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations, JAMA, 314, 2054, 10.1001/jama.2015.14905 Baade, 2009, International epidemiology of prostate cancer: geographical distribution and secular trends, Mol Nutr Food Res, 53, 171, 10.1002/mnfr.200700511 Klotz, 2007, Active surveillance for favorable-risk prostate cancer: Who, how and why?, Nat Clin Pract Oncol, 4, 692, 10.1038/ncponc0966 Thompson, 2007, Guideline for the management of clinically localized prostate cancer: 2007 update, J Urol, 177, 2106, 10.1016/j.juro.2007.03.003 Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012 07/19; 2012/07;367:203–13. Stanford, 2000, Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the prostate cancer outcomes study, JAMA, 283, 354, 10.1001/jama.283.3.354 Hamilton, 2001, Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the prostate cancer outcomes study, J Clin Oncol, 19, 2517, 10.1200/JCO.2001.19.9.2517 Stone, 2002, Complications following permanent prostate brachytherapy, Eur Urol, 41, 427, 10.1016/S0302-2838(02)00019-2 Roeloffzen, 2011, Influence of dose on risk of acute urinary retention after iodine-125 prostate brachytherapy, Int J Radiat Oncol Biol Phys, 80, 1072, 10.1016/j.ijrobp.2010.03.009 Morton, 2017, Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy, Radiother Oncol, 122, 87, 10.1016/j.radonc.2016.10.019 De la Rosette, 2010, J Endourol, 24, 775, 10.1089/end.2009.0596 Cellini, 2002, Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning, Int J Radiat Oncol Biol Phys, 53, 595, 10.1016/S0360-3016(02)02795-5 Pucar, 2008, The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery, Curr Opin Urol, 18, 87, 10.1097/MOU.0b013e3282f13ac3 Muller, 2014, Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project, BJU Int, 114, 698, 10.1111/bju.12548 Prada, 2016, High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: toxicity and long-term biochemical results, Radiother Oncol, 119, 411, 10.1016/j.radonc.2016.04.006 Hoskin, 2012, High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence, Int J Radiat Oncol Biol Phys, 82, 1376, 10.1016/j.ijrobp.2011.04.031 Barkati, 2012, High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a phase II trial, Int J Radiat Oncol Biol Phys, 82, 1889, 10.1016/j.ijrobp.2010.09.006 Yoshioka, 2011, Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions, Int J Radiat Oncol Biol Phys, 80, 469, 10.1016/j.ijrobp.2010.02.013 Demanes, 2011, High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer, Int J Radiat Oncol Biol Phys, 81, 1286, 10.1016/j.ijrobp.2010.10.015 Valerio, 2014, The role of focal therapy in the management of localised prostate cancer: a systematic review, Eur Urol, 66, 732, 10.1016/j.eururo.2013.05.048 McCulloch, 2009, No surgical innovation without evaluation: The IDEAL recommendations, Lancet, 374, 1105, 10.1016/S0140-6736(09)61116-8 Maenhout, 2018, The effect of catheter displacement and anatomical variations on the dose distribution in MRI-guided focal HDR brachytherapy for prostate cancer, Brachytherapy, 17, 68, 10.1016/j.brachy.2017.04.239 Holly, 2011, Use of cone-beam imaging to correct for catheter displacement in high dose-rate prostate brachytherapy, Brachytherapy, 10, 299, 10.1016/j.brachy.2010.11.007 Aaronson, 1993, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 85, 365, 10.1093/jnci/85.5.365 Van Andel, 2008, An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer, Eur J Cancer, 44, 2418, 10.1016/j.ejca.2008.07.030 Aaronson, 1998, Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations, J Clin Epidemiol, 51, 1055, 10.1016/S0895-4356(98)00097-3 Osoba, 1998, Interpreting the significance of changes in health-related quality-of-life scores, J Clin Oncol, 16, 139, 10.1200/JCO.1998.16.1.139 Hauswald, 2016, High-dose-rate monotherapy for localized prostate cancer: 10-year results, Int J Radiat Oncol Biol Phys, 94, 667, 10.1016/j.ijrobp.2015.07.2290 Ahmed, 2015, Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study, Eur Urol, 68, 927, 10.1016/j.eururo.2015.01.030 Nguyen, 2012, Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy, J Urol, 188, 1151, 10.1016/j.juro.2012.06.010 Laing, 2016, Hemi-gland focal low dose rate prostate brachytherapy: an analysis of dosimetric outcomes, Radiother Oncol, 121, 310, 10.1016/j.radonc.2016.09.014 Groenendaal, 2010, Validation of functional imaging with pathology for tumour delineation in the prostate, Radiother Oncol, 94, 145, 10.1016/j.radonc.2009.12.034 Breeuwsma, 2010, Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography, Int J Radiat Oncol Biol Phys, 77, 160, 10.1016/j.ijrobp.2009.04.090 Ganzer R, Arthanareeswaran VKA, Ahmed HU, Cestari A, Rischmann P, Salomon G, et al. Which technology to select for primary focal treatment of prostate cancer?-European Section of Urotechnology (ESUT) position statement. Prostate Cancer Prostatic Dis. 2018 May 9. doi:10.1038/s41391-018-0042-0. [Epub ahead of print].